Our results suggest that LIG1-specific inhibitors could expand the opportunities for PCa and BRCA patient treatment, whereas other tumor types, such as LUAD and COAD, seem to be less responsive to the combined pharmacological inhibition of LIG1 and PARP. This evidence concerns the gene PARP1 and neoplasm.